Guided Therapeutics (GTHP) Income from Continuing Operations (2010 - 2025)
Guided Therapeutics (GTHP) reported Income from Continuing Operations of 1218000.0 for Q4 2025, down 86.81% on a YoY basis from 9234139.53 in Q4 2024, and down 64.15% sequentially from 742000.0 in Q3 2025.
Guided Therapeutics (GTHP) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Income from Continuing Operations data on file, last reported at 1218000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 86.81% year-over-year to 1218000.0; the trailing twelve-month figure through Dec 2025 stood at 3198000.0 (down 32.31% YoY), and the FY2025 full-year result was 3196000.0, down 32.23% from the prior year.
- Income from Continuing Operations fell to 1218000.0 in Q4 2025, from 742000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 68000.0 in Q3 2021 to a low of 1807000.0 in Q4 2022.
- A 5-year average of 768650.0 and a median of 693000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 84.68% in 2021 and plunged 1720.59% in 2022, its largest moves.
- Tracing GTHP's Income from Continuing Operations over 5 years: stood at 444000.0 in 2021, then tumbled by 306.98% to 1807000.0 in 2022, then jumped by 78.64% to 386000.0 in 2023, then tumbled by 68.91% to 652000.0 in 2024, then sank by 86.81% to 1218000.0 in 2025.
- Business Quant data shows GTHP's Income from Continuing Operations at 1218000.0 in Q4 2025, 742000.0 in Q3 2025, and 811000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -742,000.00 |
| Jun 30, 2025 | -811,000.00 |
| Mar 31, 2025 | -427,000.00 |
| Dec 31, 2024 | -652,000.00 |
| Sep 30, 2024 | -654,000.00 |
| Jun 30, 2024 | -709,000.00 |
| Mar 31, 2024 | -402,000.00 |
| Dec 31, 2023 | -386,000.00 |
| Sep 30, 2023 | -677,000.00 |
| Jun 30, 2023 | -1.56 Mn |
| Mar 31, 2023 | -869,000.00 |
| Dec 31, 2022 | -1.81 Mn |
| Sep 30, 2022 | -1.10 Mn |
| Jun 30, 2022 | -926,000.00 |
| Mar 31, 2022 | -507,000.00 |
| Dec 31, 2021 | -444,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | -1.03 Mn |
| Mar 31, 2021 | -517,000.00 |